Efficacy of Metreleptin in Obese Patients With Type 2 Diabetes: Cellular and Molecular Pathways Underlying Leptin Tolerance
Hyun‐Seuk Moon(Harvard University), Christos S. Mantzoros(Beth Israel Deaconess Medical Center), Fortunata Carbone(Institute for Experimental Endocrinology and Oncology), Luisa Abanni(Institute for Experimental Endocrinology and Oncology), John P. Chamberland(Beth Israel Deaconess Medical Center), Geetha Mylvaganam(Beth Israel Deaconess Medical Center), Giuseppe Matarese(Federico II University Hospital), Christina G. Fiorenza(Beth Israel Deaconess Medical Center), Benjamin E. Schneider(Beth Israel Deaconess Medical Center), Xiaowen Liu(Beth Israel Deaconess Medical Center), Aoife Brennan(Beth Israel Deaconess Medical Center), Alex M. De Paoli(Amgen (United States)), Catherine J. Williams(Beth Israel Deaconess Medical Center)
Cited by 150
Related Papers
Role of leptin in the neuroendocrine response to fasting
|Nature|1996|3.1k
Adverse metabolic and cardiovascular consequences of circadian misalignment
|Proceedings of the National Academy of Sciences|2009|2.3k
Obesity and cancer risk: Emerging biological mechanisms and perspectives
|Metabolism|2018|1.6k
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
|Metabolism|2018|1.2k